Crossmark

Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors

Crossref DOI link: https://doi.org/10.1038/s41467-025-59021-9

Published Online: 2025-07-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sek, Kevin https://orcid.org/0000-0003-4634-7600
Chen, Amanda X. Y.

Cole, Thomas

Armitage, Jesse D.

Tong, Junming https://orcid.org/0009-0006-6454-8704
Yap, Kah Min https://orcid.org/0000-0001-5009-9895
Munoz, Isabelle https://orcid.org/0000-0001-6510-5696
Dunbar, Phoebe A.

Wu, Shiyi

van Elsas, Marit J.

Hidajat, Olivia

Scheffler, Christina https://orcid.org/0000-0003-3731-6204
Giuffrida, Lauren

Henderson, Melissa A.

Meyran, Deborah https://orcid.org/0000-0003-2723-8185
Souza-Fonseca-Guimaraes, Fernando https://orcid.org/0000-0002-2037-8946
Nguyen, Dat

Huang, Yu-Kuan https://orcid.org/0000-0003-2262-7069
de Menezes, Maria N. https://orcid.org/0000-0003-3231-0620
Derrick, Emily B. https://orcid.org/0000-0001-7191-3948
Chan, Cheok Weng

Todd, Kirsten L. https://orcid.org/0000-0002-3903-166X
Chan, Jack D. https://orcid.org/0000-0002-5942-8592
Li, Jasmine

Lai, Junyun

Petley, Emma V.

Mardiana, Sherly

Bosco, Anthony https://orcid.org/0000-0002-4335-615X
Waithman, Jason

Parish, Ian A. https://orcid.org/0000-0003-3528-478X
Mølck, Christina

Stewart, Gregory D. https://orcid.org/0000-0002-9748-4990
Kats, Lev https://orcid.org/0000-0001-8742-8138
House, Imran G. https://orcid.org/0000-0002-6245-5954
Darcy, Phillip K. https://orcid.org/0000-0002-5303-9561
Beavis, Paul A. https://orcid.org/0000-0002-2116-013X
Funding

Funding for this research was provided by:

Cancer Council Victoria (836379)
License Information

Text and Data Mining valid from 2025-07-03

Version of Record valid from 2025-07-03
More Information

Article History

Received: 4 March 2024

Accepted: 7 April 2025

First Online: 3 July 2025

Competing interests

: P.A.B. declares the following conflicts; Research funding: Gilead, Bristol Myers Squibb. P.K.D. declares the following conflicts: research funding from Myeloid Therapeutics, Prescient Therapeutics and Bristol-Myers-Squibb. K.S. declares the following conflicts: Research funding: Prescient Therapeutics. I.A.P. declares the following conflicts; Research funding: AstraZeneca, Bristol Myers Squibb. A.B. declares the following conflicts: Founder of INSiGENe Pty Ltd, which is related to this work. Co-founder and director of Respiradigm Pty Ltd that is unrelated to this work. All other authors declare no conflict of interest.

Document is current

Any future updates will be listed below